




The relative strengths and weaknesses of Insys Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Insys Therapeutics Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 82% points. The greatest weakness of Insys Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 350%, being 87% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	253,238
Cost of Goods Sold	28,854
Intangible Assets	0
Liabilities, Current	88,859
Liabilities, Non-Current	0
Other Assets	59,576
Other Compr. Net Income	-128
Other Expenses	124,675
Other Liabilities	8,635
Other Net Income	538
Other Revenues	330,797
Property and Equipment	38,382
Research and Development	55,281
Selling, General and Administrative Expense	64,049

Output Variable	Value in 1000 USD
Assets	351,196
Liabilities	97,494
Expenses	272,859
Revenues	330,797
Stockholders Equity	253,702
Net Income	58,476
Comprehensive Net Income	58,412
BaseVar	526,506
ECR before LimitedLiability	273%
Economic Capital Ratio	350%